Author

M. Altun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

J. Bostrom· 2 shared A. Harisankar· 1 shared A. Rasti· 1 shared A. Throup· 1 shared A.-L. Gustavsson· 1 shared B. D. G. Page· 1 shared D. Rehling· 1 shared F. Salomons· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. Bostrom

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM

N. C. K. Valerie, K. Sanjiv, O. Mortusewicz, S. M. Zhang, S. Alam, M. J. Pires, H. Stigsdotter, A. Rasti, M.-F. Langelier, D. Rehling, A. Throup, M. Desroses, J. Onireti, P. Wakchaure, I. Almlof, , M. Altun

CeTEAM evaluates drug-target interactions and phenotypic responses using biosensors, revealing how drug binding affects cellular activities and metabolism.

bioRxiv · Sep 19, 2022Biochemistry

Identification of GTF2IRD1 as a novel transcription factor essential for acute myeloid leukemia

Y. Heshmati, G. Turkoz, J. Zawacka, M. Dimitriou, A. Harisankar, J. Bostrom, H. Cai, N. Kadri, M. Altun, H. Qian, J. Walfridsson

This study identifies GTF2IRD1 as a novel transcription factor essential for AML cell survival and disease progression, with potential therapeutic implications.

bioRxiv · Aug 9, 2022 · PreprintCancer Biology

Inhibition of the ubiquitin-proteasome system by a bioactivatable compound

T. A. Giovannucci, F. Salomons, M. Haraldsson, L. Elfman, M. Wickstrom, P. Young, T. Lundback, J. Eirich, M. Altun, R. Jafari, A.-L. Gustavsson, J. I. Johnson, N. Dantuma

The paper identifies CBK77, a bioactivatable compound that inhibits the ubiquitin-proteasome system by targeting NQO1, leading to cell death in cancer cells.

bioRxiv · Mar 16, 2021Cell Biology